Regulus Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Hi, everyone, welcome, and thanks for attending Canaccord Genuity's 43rd annual growth conference. My name is Joohwan Kim, and I'm an associate on Whitney Ijem's genetic medicine and rare disease team.
We're very excited to have the team from Regulus Therapeutics here. It's my great pleasure to introduce the CEO, Mr. Jay Hagan. Regulus Therapeutics is a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs.
And so with that, I'll turn it over to the team for a presentation.
Questions & Answers
Thanks very much and thanks to the entire team at Canaccord for giving us the opportunity to provide an update today on our programs. I will be making forward-looking statements. Actual results may differ materially from those discussed today. So I encourage you to read our risk factors in our SEC filings, including our 10-Q that we filed yesterday afternoon.
So Regulus Therapeutics is a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |